Evaluating the efficacy of palbociclib/palbociclib in the treatment of breast cancer

Palbociclib/Palbociclib plays an important role in the treatment of breast cancer, especially in the treatment of adult patients with advanced or metastatic breast cancer. This drug is mainly suitable for patients who are human epidermal growth factor receptor type 2 (HER2) negative and hormone receptor (HR) positive. It can be used in combination with letrozole as initial endocrine therapy or with fulvestrant in patients whose disease has progressed despite prior endocrine therapy. When used, palbociclib is often combined with an aromatase inhibitor (not limited to letrozole) as the preferred endocrine therapy option for postmenopausal women or men.

Palbociclib belongs to a class of drugs called kinase inhibitors. It works by blocking the action of abnormal proteins that signal cancer cells to proliferate. This helps stop or slow the spread of cancer cells.

United StatesFDA’s approval of palbociclib was based on its excellent clinical trial results. Among them, the PALOMA 2 study compared the effect of palbociclib combined with letrozole and letrozole alone. The study included 165 postmenopausal women with ER-positive, HER2-negative advanced breast cancer who had not received prior systemic therapy for advanced disease. The trial results showed that the median progression-free survival (PFS) of patients who received the combination of palbociclib plus letrozole reached 24.8 months, while the PFS of patients who received letrozole alone was only 14.5 months. Among subjects with measurable disease, the overall response rate in the combination group was also significantly higher than that in the monotherapy group (55.4% vs. 39.4%).

Another international clinical trial calledPALOMA-3 studied the efficacy of palbociclib plus fulvestrant compared with placebo plus fulvestrant in women with HR-positive, HER2-negative advanced breast cancer. This study showed a significant advantage of palbociclib plus fulvestrant regardless of the patient's menopausal status or previous endocrine therapy. Among them, the median PFS was 9.5 months, which was much higher than the 4.6 months of placebo plus fulvestrant. In addition, the objective response rate of the combination group also reached 24.6%, which was much higher than the 10.9% of the control group.

Patients should consult their primary care physician before using palbociclib. Doctors and researchers will comprehensively evaluate the effect of palbociclib treatment based on the patient's specific situation and adjust the treatment plan as needed to ensure that the patient gets the best treatment effect. At the same time, the individual differences of patients and the complexity of the disease need to be fully considered during the assessment process. If the patient has more questions about palbociclib, please consult a Yaofenxiang medical consultant for more information.